Colorectal Cancer

Globally, colorectal cancer is the third most common type of cancer making up about 10% of all cancer cases. In 2012 there were 1.4 million new cases and 694,000 deaths from colorectal cancer1. The 5-year survival rates in the United States are around 65%.

Colorectal cancer typically starts with a benign tumour

Colorectal cancer typically starts with a benign tumour, often in the form of a polyp, which over time becomes cancerous1. Treatment options are depending on the stage of the disease, overall health and preferences of the patient2. Standard treatments include surgery, chemotherapy, radiotherapy or a combination3.


References:

1. Colorectal cancer,
    Wikipedia, last edited January 2018

2. Current standards and new trends in the primary treatment of colorectal cancer
    Stein, Alexander et al., European Journal of Cancer , Volume 47 , S312 - S314, Sep. 2011

3. Colon Cancer Treatment (PDQ®) – Patient Version,
    National Cancer Institute, updated December 2017

  1. Lonsurf (trifluridine/tipiracil)
    Lonsurf (trifluridine/tipiracil)
    by Les Laboratoires Servier
    for Colorectal Cancer
    €857.04
  2. Opdivo (nivolumab)
    Opdivo (nivolumab)
    by Bristol-Myers Squibb Pharma EEIG
    for Urothelial Carcinoma, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer
    €540.50
View as Grid List

2 Items

per page
Set Descending Direction

One more step before you can continue

Our service contains information about acquiring medicines that have been approved in another country. This includes professional information such as approval details, product information and pricing. By scrolling, you are declaring that you are requesting any such information.

Scroll down.

No, I'd like to receive general information only.

Disclaimer: The information TSM provides is aimed at patients with terminal and life-debilitating diseases, their doctors and healthcare professionals. It supports an informed decision by the treating doctor about the patient’s treatment and the consideration of a medicine which has not been approved in the patient’s country.